|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Thoracic Oncology Program, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston
Because small cell lung cancer (SCLC) is very responsive to chemotherapy, an attempt at treatment is warranted even in poor-prognosis patients with limited-stage disease. Concurrent thoracic radiotherapy and prophylactic cranial irradiation should be considered in such cases. A case report of an elderly, debilitated patient with limited-stage SCLC is presented, and his management is discussed.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |